

Metaraminol

SALAD							
Metaraminol and Metoclopramide							
CAUTION: High Administration Risk Rating							
Form	<ul style="list-style-type: none">10mg/mL ampoule2.5mg in 5mL Pre Filled Syringe (0.5mg/ml)						
Reconstitution	Already in solution Using ampoule <ul style="list-style-type: none">Draw up using a 5micron filter needleUse gloves when opening ampoules						
Compatibility & Stability	Glucose 5% Sodium Chloride 0.9%						
Administration	IV Injection						
	Use PreFilled Syringe PFS (2.5mg in 5mL = 0.5mg/mL) where available						
	In an emergency, give 500microgram - 1000microgram (1-2ml) bolus slowly over 2-5 minutes as required according to response, followed by an infusion.						
	If PFS not available prepare a 0.5mg/mL solution						
	<table><tr><th>Volume of metaraminol</th><th>Volume of compatible Fluid</th><th>Final Conc</th></tr><tr><td>1mL</td><td>19mL</td><td>0.5mg/mL (500 microgram/mL)</td></tr></table>	Volume of metaraminol	Volume of compatible Fluid	Final Conc	1mL	19mL	0.5mg/mL (500 microgram/mL)
Volume of metaraminol	Volume of compatible Fluid	Final Conc					
1mL	19mL	0.5mg/mL (500 microgram/mL)					
Administration	IV Infusion						
	Prepare 0.5mg/mL solution as per table below						
	<table><tr><th>Volume of metaraminol</th><th>Volume of compatible Fluid</th><th>Final Conc</th></tr><tr><td>2mL</td><td>38mL</td><td>0.5mg/mL (500 microgram/mL)</td></tr></table>	Volume of metaraminol	Volume of compatible Fluid	Final Conc	2mL	38mL	0.5mg/mL (500 microgram/mL)
	Volume of metaraminol	Volume of compatible Fluid	Final Conc				
	2mL	38mL	0.5mg/mL (500 microgram/mL)				
Preferably give via a central venous access device using an infusion pump at a rate up to 10mg/hour (20mL/hour of 0.5mg/mL).							
If a central venous access device is unavailable, administer via a large peripheral vein monitoring insertion site. Resite cannula at first signs of inflammation.							
After discontinuation, flush the peripheral cannula with sodium chloride 0.9% at the same rate the medicine was infused to avoid an unintentional 'bolus' dose. Discard the IV administration set before flushing the cannula. Peripheral cannula: Flush if it is to remain in situ. Central venous access device: Aspirate the cannula contents before flushing.							
Monitoring	<ul style="list-style-type: none">Monitor blood pressure, heart rate, ECG, central venous pressure, drowsiness, urine output, potassium levels, lactate levels.						
Extravasation	<ul style="list-style-type: none">Extravasation is likely to cause tissue damage because metaraminol is a potent vasoconstrictor and has a low pH.						
Additional Information	<ul style="list-style-type: none">Maximum effects are not immediately apparent: at least 10 minutes should elapse between dose increases						

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications.
 Further information is available from Pharmacy on 22146 or 22542

- | | |
|--|---|
| | <ul style="list-style-type: none">• Metaraminol has a longer duration of action than noradrenaline, and an excessive vasopressor response may cause a prolonged rise in blood pressure. |
|--|---|

Information relates to Metaraminol (Flexipham Austrading)